Treatment of psoriasis through down-regulation of the...

Details Treatment of psoriasis through down-regulation of the... Treatment of psoriasis through down-regulation of the...

2006-03-21

2006-03-21

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S275000

Reexamination Certificate

active

07015199

ABSTRACT:
Topical agent formulations for the treatment of psoriasis containing epidermal growth factor (EGF) as the active agent. EGF precursors or biological equivalents can be used. The formulation can also contain an anti-inflammatory. The formulation can contain sulfadiazine.

REFERENCES:
patent: 5070188 (1991-12-01), Njieha et al.
patent: 5130298 (1992-07-01), Cini et al.
patent: 6337320 (2002-01-01), Hersh et al.
patent: 0 339 905 (1989-11-01), None
Nanney et al. Modulation of Epidermal Growth Factor Receptors in Psoriatic Lesions During Treatment with Topical EGF. J. Invest. Dermatol. Mar. 1992, vol. 98, No. 3, pp. 296-301.
Phan et al. Association Between Pyoderma Gangrenosum And Psoriasis. Lancet. Aug. 24, 1996. vol. 348, p. 547.
Casaco et al. Topical Anti-Inflammatory Activity of Human Recombinant Epidermal Growth Factor. Skin Pharmacol. Appl. Skin Physiol. 1999. vol. 12, pp. 79-84.

Affiliated with

Also associated with

Rating

Treatment of psoriasis through down-regulation of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of psoriasis through down-regulation of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of psoriasis through down-regulation of the... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3596877